| Company/Division name | Enzene Biosciences, Ltd |
| Parent company | Alkem Laboratories |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 300 |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 50 |
| Country(ies) from which reshored: | India |
| City reshored to: | Hopewell |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biotechnology |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Higher productivity, Infrastructure, Proximity to customers/market, Skilled workforce availability/training |
